NFKB1 and diabetes mellitus: Previous studies have shown that luteolin inhibits high-glucose-induced activation of NF-κB in human monocytes and the release of the proinflammatory factor TNF-α, with potential preventive and therapeutic activity in diabetes mellitus [29].